Losortan Potassium
Product Images NDC 53002-7624

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 53002-7624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

Chemical structure of losartan potassium, showing its molecular components including the tetrazole ring, biphenyl group, and potassium ion.*

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

A line graph comparing the percentage of patients with a primary endpoint over time between Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage from 0% to 16%. Atenolol is depicted with a dashed line, Losartan Potassium with a solid line, indicating an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

A line graph comparing the percentage of patients with fatal or non-fatal strokes over time between Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows the percentage of patients. The graph indicates adjusted risk reduction of 25% with Losartan Potassium (p=0.001).*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

A forest plot chart comparing primary composite and stroke (fatal/non-fatal) event rates between Losartan-K and Atenolol in various patient subgroups. It presents hazard ratios with 95% confidence intervals, event rates, and number of patients classified by age, gender, race, ischemic heart disease, diabetes, and cardiovascular disease history.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium Tablet and placebo groups. The Losartan Potassium group shows a lower event rate, with a reported risk reduction of 16.1% (p=0.022). The x-axis represents time in months, and the y-axis represents the percentage of patients with an event.*

FDA Label Image

Label Image (Lbl530027624)

Packaging label for Losortan Potassium 25mg tablets by RPK Pharmaceuticals, Inc. The carton contains 100 tablets with dosing directions to take 1 tablet daily as directed. The label includes space for patient and clinic information, barcode, NDC number 53002-7624, and expiration date details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.